ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GPC3 T Cell-engaging Antibody AZD9793

Also written as “AZD9793 Intravenous (IV) monotherapy” and “AZD9793 Subcutaneous (SC) monotherapy”.

Its studies are mostly in Carcinoma, Hepatocellular, led by AstraZeneca.

Furthest: phase 2, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Jan 8, 2025Jan 8, 2025Jun 30, 2027phase 2 · NCT06795022

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06795022 · 304 planned · United States, China, Hong Kong and more

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06795022

TargetBeta

“A T-cell engaging (TCE) asymmetric trispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3 TCE an…”NCIt, read by Claude
“A T-cell engaging (TCE) asymmetric trispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06795022Carcinoma, Hepatocellular · United States, China, Hong Kong and more2RecruitingJun 30, 2027304

How it is read

Names in the registry

  • “AZD9793 Intravenous (IV) monotherapy”, 1 entry
  • “AZD9793 Subcutaneous (SC) monotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.